TB-500 Legal Status, FDA 503A Category, and Compounding Access

The current fact: 503A Category 2

On TB-500 legal status, the present-tense fact is precise and FDA-sourced. FDA identifies the substance on its list as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — FDA's own entry establishes that TB-500 is the LKKTETQ fragment associated with the thymosin beta-4 peptide [reg1]. FDA placed that substance in 503A "Category 2" — bulk drug substances that may present significant safety risks — effective with its September 29, 2023 update to the list of substances nominated for use under section 503A, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information [reg1].

Two consequences follow directly from Category 2. First, as a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding; FDA has stated it would consider taking action against a compounder for compounding with such a substance [reg3]. Second — and separately — TB-500 is not an FDA-approved drug [reg1]. Approval of a finished drug is a different question from whether a bulk substance may be used in compounding, and TB-500 satisfies neither.

Access is under active review and may expand in 2026

The forward-leaning part of this story is real, and it is anchored to a published FDA fact. "TB-500 (free base)" and "TB-500 acetate" appear, individually named, on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as bulk drug substances "being considered for inclusion on the 503A Bulks List" [reg2]. The same agenda lists BPC-157, KPV, and MOTs-C. Access to compounded TB-500 is, in other words, under active FDA review, and the framework that currently excludes it is the same framework that could, in principle, change.

The hedge is just as real, and it is non-negotiable. A PCAC meeting is a scheduled evaluation and discussion only. It is advisory; it is not a listing decision, not a reclassification, and not a change in current status [reg2]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — being discussed by the committee is a step in evaluation, not an outcome [reg3]. As of the cited FDA pages, the last confirmable FDA action for TB-500 remains its Category 2 placement. No reclassification of TB-500 has occurred, none is dated, and none is certain. Reports circulating in 2026 of peptides being "moved back" toward Category 1 or "removed" from Category 2 could not be confirmed from an authoritative FDA source and are not treated here as fact.

How legally compounded peptide access works

Independently of where TB-500 sits, it is worth understanding the lawful compounding pathway in general terms. Under the Federal Food, Drug, and Cosmetic Act, compounding runs through two sections: 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians pursuant to a valid prescription for an individual patient, and 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [reg3].

The sequence is consistent. A patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [reg4]. If it is, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [reg4].

Telehealth, where it appears, is a front-end consultation channel for that prescriber-evaluation step — a route to a licensed consultation and a prescription. It does not change which substances may be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription [reg4].

The ingredient-eligibility caveat is the part that bears on TB-500 directly. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list [reg3]. A substance FDA has flagged for significant safety risks — a Category 2 substance — is not eligible for routine 503A compounding while that status stands [reg4]. That eligibility caveat applies to TB-500 today, and it is what the July 2026 evaluation concerns.

This page names no pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain a restricted substance outside the lawful framework. It is general information about the regulatory landscape — not medical or legal advice, and not an offer to sell or supply any substance.

WADA prohibition and doping detection

Beyond compounding, TB-500 carries a clear sport-doping status. TB-500 and thymosin beta-4 fall under WADA prohibited peptide and growth-factor and tissue-repair categories, banned in and out of competition for the relevant classes, and detectable by LC-MS anti-doping assays. It is also classified as a prescription medicine in some jurisdictions, such as Australia and New Zealand.

Is TB-500 banned by WADA?

Yes. TB-500 and thymosin beta-4 fall under WADA prohibited peptide, growth-factor, and tissue-repair categories, banned in and out of competition, and are detectable by LC-MS anti-doping assays.

Why is TB-500 associated with racehorses?

TB-500 has been encountered as a designer substance in equine sport, which is why the first validated LC-MS detection methods (with limits of detection around 0.01–0.02 ng/mL) were developed in horses. It is prohibited in regulated racing.

Is TB-500 FDA approved?

No. FDA lists the LKKTETQ fragment as TB-500 and has placed it in 503A Category 2; it has no FDA-approved therapeutic indication and is not an FDA-approved drug [reg1]. It is supplied as a research and veterinary-context substance, not an approved medicine.